Edgewell Personal Care Company
NYSE:EPCHousehold & Personal Products
+$1.26 today
- Market cap
- $1.30B
- Beta
- 0.49
- P/E (TTM)
- -14.2
- EPS (TTM)
- -$1.67
- Dividend yield
- 2.52%
Volume 0.50M
Average 0.79M
EPC Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Edgewell Personal Care CompanyNYSE: EPC
Research & Development · Q2 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q2 FY2026 research & development of $14.9M rose 7.2% year over year, ahead of the -0.3% change in trailing-twelve-month research & development. Sequentially, it rose 8.0% from the prior quarter. Over 3 fiscal years it compounded at +1.2% a year.
Context
- Research & development amounted to 2.6% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +7.2% holds above the trailing-twelve-month pace of -0.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 57.6M USD
- Year-over-year change
- -1.4%
- 4-year CAGR
- -0.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 57.6M | -1.4% |
| FY2024 | 2024-09-30 | 58.4M | -0.2% |
| FY2023 | 2023-09-30 | 58.5M | +5.4% |
| FY2022 | 2022-09-30 | 55.5M | -4.0% |
| FY2021 | 2021-09-30 | 57.8M | — |
Research & Development vs competitors
How EPC compares with its peers on the latest reported figures
- EPC's LTM Mar 2026 research & development of $58.5M is the highest of the 9 companies compared; the peer median is $0.
- Its year-over-year change of -0.3% is the highest of 3, against a peer median of -38.3%.
- Research & development amounts to 2.8% of revenue for EPC, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $58.5M | -0.3% | +1.2% | 2.8% | |
| LTM Mar 2026 | $10.8M | -16.9% | — | 0.7% | |
| LTM Jun 2026 | $10.7M | -59.8% | — | 0.4% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Apr 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding EPC) | $0 | -38.3% | — | 0.0% | |
Competitors are the stored peer set for EPC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 2.09B | 2.17B | 2.25B | 2.25B | 2.22B |
| Cost of Revenue | 1.14B | 1.29B | 1.31B | 1.3B | 1.3B |
| Gross Profit | 951.2M | 880.5M | 940.8M | 955.7M | 924.9M |
| Gross Margin | 45.6% | 40.5% | 41.8% | 42.4% | 41.6% |
| Research & Development | 57.8M | 55.5M | 58.5M | 58.4M | 57.6M |
| Selling, General & Admin | 632.7M | 627.4M | 638.7M | 662.1M | 671.7M |
| Operating Expenses | 711.3M | 698.2M | 713.8M | 756.4M | 828.3M |
| Depreciation & Amortization | 87.1M | 89.9M | 91.4M | 88M | 88.8M |
| EBITDA | 302.1M | 285.4M | 317.6M | 285.4M | 185.6M |
| EBITDA Margin | 14.5% | 13.1% | 14.1% | 12.7% | 8.3% |
| Operating Income | 239.9M | 182.3M | 227M | 199.3M | 96.6M |
| Operating Margin | 11.5% | 8.4% | 10.1% | 8.8% | 4.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 67.9M | 71.4M | 78.5M | 76.5M | 73.2M |
| Other Income / Expenses | (92.8M) | (58.2M) | (79.3M) | (78.4M) | (73M) |
| Income Before Tax | 147.1M | 124.1M | 147.7M | 120.9M | 23.6M |
| Pre-Tax Margin | 7.0% | 5.7% | 6.6% | 5.4% | 1.1% |
| Income Tax Expense | 29.3M | 24.6M | 33M | 22.3M | (1.8M) |
| Net Income | 117.8M | 99.5M | 114.7M | 98.6M | 25.4M |
| Net Margin | 5.6% | 4.6% | 5.1% | 4.4% | 1.1% |
| EPS (Basic) | 2.15 | 1.87 | 2.24 | 1.98 | 0.53 |
| EPS (Diluted) | 2.12 | 1.86 | 2.21 | 1.97 | 0.53 |
| Weighted Avg Shares | 54.4M | 53.1M | 51.2M | 49.7M | 47.5M |
| Weighted Avg Shares (Diluted) | 55.2M | 53.6M | 51.8M | 50.1M | 47.6M |
Edgewell Personal Care Company
NYSE:EPC
Intrinsic Alpha fair value
Locked
Current Price
$28.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.